Last updated: 02/04/2020 15:40:09

PGx6557: Targeted Genotyping in lapatinib DILI positive re-challenge cases from EGF106708 and EGF106903

GSK study ID
117393
See study documents
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Finalized
Finalized
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: PGx6557: Targeted Genotyping in lapatinib DILI positive re-challenge cases from EGF106708 and EGF106903
Trial description: HLA markers (HLA-DRB1*07:01, HLA-DQA1*02:01, HLA-DQB1*02:01) have been confirmed to be associated with alanine aminotransferase (ALT) elevation in lapatinib-treated subjects. This PGx experiment aims to assess carriage of these pre-specified risk markers in lapatinib drug-induced liver injurty (DILI) positive re-challenge cases.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

Assess carriage of these pre-specified risk markers in lapatinib drug-induced liver injurty (DILI) positive re-challenge cases.

Timeframe: N/A

Secondary outcomes:
Not applicable
Interventions:
Drug: lapatinib
Enrollment:
0
Observational study model:
Case-Only
Primary completion date:
2014-17-06
Time perspective:
Retrospective
Clinical publications:
Not applicable
Medical condition
Neoplasms, Breast
Product
lapatinib
Collaborators
Not applicable
Study date(s)
October 2012 to June 2014
Type
Observational
Phase
Not applicable

Participation criteria

Sex
Female
Age
Not applicable
Accepts healthy volunteers
none
  • Patients who provided written informed consent for PGx research when they enrolled in the clinical studies EGF106708 and EGF106903
  • Patients defined as a positive rechallenge DILI case by the GSK Hepatotoxicity panel
  • Patients that did not provide written informed consent for PGx research when they enrolled in the clinical studies EGF106708 and EGF106903
  • Patients that are not defined as a positive rechallenge DILI case by the GSK Hepatoxicity panel
Inclusion and exclusion criteria
Inclusion criteria:
  • Patients who provided written informed consent for PGx research when they enrolled in the clinical studies EGF106708 and EGF106903
  • Patients defined as a positive rechallenge DILI case by the GSK Hepatotoxicity panel
  • Patients that had a PGx sample and genetic data available.
Exclusion criteria:
  • Patients that did not provide written informed consent for PGx research when they enrolled in the clinical studies EGF106708 and EGF106903
  • Patients that are not defined as a positive rechallenge DILI case by the GSK Hepatoxicity panel
  • Patients that had an ALT elevation upon treatment with lapatinib but were not defined as a positive rechallenge DILI case by the GSK Hepatotoxicity panel
  • Patients that did not have a PGx sample or genetic data available.

Trial location(s)

No location data available.

Study documents

Scientific result summary
Available language(s): English
Download document(s)

If you wish to request for full study report, please contact - [email protected]

Results overview

Refer to study documents

Recruitment status
Finalized
Actual primary completion date
2014-17-06
Actual study completion date
2014-17-06

Plain language summaries

Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

Additional information about the trial

Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website